Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland

Osteoporosis International

Volumn 23, Issue 11, 2012, Pages 2579-2589

  Lippuner, K ^a,e   Johansson, H ^b   Borgstrom F ^c   Kanis, J A ^b   Rizzoli, R ^d  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d University Hospital and Medical ^*  (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

10 year fracture probability; Alendronate; Cost effectiveness; FRAX ; Intervention thresholds; Osteoporosis; Switzerland

Indexed keywords

ALENDRONIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; FRACTURE RISK ASSESSMENT ALGORITHM; FRAGILITY FRACTURE; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; RISK REDUCTION; SWITZERLAND;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ALENDRONATE; ALGORITHMS; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SWITZERLAND;

EID: 84864565291     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1869-6     Document Type: Article

References (84)

1. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428
2. Lippuner K, Golder M, Greiner R (2005) Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int 16(Suppl 2):S8-S17
3. Lippuner K, Johansson H, Kanis JA, Rizzoli R (2009) Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int 20:1131-1140
4. Robine JM, Paccaud F (2005) Nonagenarians and centenarians in Switzerland, 1860-2001: a demographic analysis. J Epidemiol Community Health 59:31-37
5. Bundesamt für Statistik. Szenarien zur Bevölkerungsentwicklung der Schweiz 2005-2050. http://www.bfs.admin.ch/bfs/portal/de/index/news/ publikationen.Document.83713.pdf. Last visited May 14, 2008.
6. Schwenkglenks M, Lippuner K, Hauselmann HJ, Szucs TD (2005) A model of osteoporosis impact in Switzerland 2000-2020. Osteoporos Int 16:659-671
7. (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94(6):646-650
8. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9: 1137-1141
9. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467-475
10. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929-1936
11. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259
12. Cummings SR, Black D (1995) Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med 98:24S-28S
13. (2011) Bundesamt für Gesundheit (BAG). List of reimbursed medicines in Switzerland (Spezialitätenliste). http://www.sl.bag.admin.ch
14. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585-590
15. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815-2822
16. Suhm N, Lamy O, Lippuner K (2008) Management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Med Wkly 138(45-46):674-683
17. Chevalley T, Hoffmeyer P, Bonjour JP, Rizzoli R (2002) An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporos Int 13:450-455
18. Lippuner K, Johansson H, Kanis JA, Rizzoli R (2010) FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int 21:381-389
19. Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Assessment of fracture risk. Eur J Radiol 71:392-397
20. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX assessment and intervention thresholds for the UK. Osteoporos Int 19:1395-1408
21. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19:449-458
22. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437-447
23. Dawson-Hughes B (2008) A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 93:2463-2465
24. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105-108
25. (2010) National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. http://www.nof.org/professionals/clinical- guidelines.
26. Papaioannou A, Morin S, Cheung AM et al (2010) 2010 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Cmaj 182:1864-1873
27. (1999) Royal College of Physicians. Osteoporosis: clinical guidelines for the prevention and treatment. London, Royal College of Physicians
28. (2010) Diagnostik, Prävention und Behandlung der Osteoporose: Empfehlungen der Schweizerischen Gesellschaft gegen Osteoporose (SVGO). http://www.svgo.ch/. Last visited August 8, 2011:
29. Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E (2009) FRAX and its applications to clinical practice. Bone 44:734-743
30. Kanis J (2007) World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. Technical report. World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK.
31. Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033-1046
32. Krieg MA, Cornuz J, Ruffieux C et al (2006) Prediction of hip fracture risk by quantitative ultrasound in more than 7000 Swiss women or 070 years of age: comparison of three technologically different bone ultrasound devices in the SEMOF study. J Bone Miner Res 21:1457-1463
33. Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316:736-741
34. Borgstrom F, Zethraeus N, Johnell O et al (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17:637-650
35. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20-26
36. Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4-15
37. Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jonsson B (2005) Intervention thresholds for osteoporosis in the UK. Bone 36:22-32
38. Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C, Jonsson B (2005) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16:6-14
39. Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model. Osteoporos Int 18:9-23
40. Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495-505
41. Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey E, Kanis JA (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 21:339-349
42. Borgstrom F, Carlsson A, Sintonen H, Boonen S, Haentjens P, Burge R, Johnell O, Jonsson B, Kanis JA (2006) The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 17:996-1007
43. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417-427
44. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669-674
45. (2008) Life tables for WHO member states. Switzerland. Accessed May 12, 2011.
46. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38-42
47. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599-603
48. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108-112
49. Poor G, Atkinson EJ, O'Fallon WM, Melton LJ 3rd (1995) Determinants of reduced survival following hip fractures in men. Clin Orthop Relat Res (319):260-265
50. Parker MJ, Anand JK (1991) What is the true mortality of hip fractures? Public Health 105:443-446
51. (2008) NICE. Osteoporosis - secondary prevention including strontium ranelate: appraisal consultation document. http://guidance.nice.org.uk/TA161 under www.nice.org.uk. Accessed May 12, 2011.
52. Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967-982
53. (2008) National Institute for Health and Clinical Excellence (NICE). Systematic reviews of clinical effectiveness prepared for the guideline 'Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk' http://www.nice.org.uk/nicemedia/live/ 11621/42362/42362.pdf. Last visited April1 8, 2011.
54. Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862-871
55. Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16:15-25
56. Schwenkglenks M, Lippuner K (2007) Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporos Int 18:1481-1491
57. Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031
58. Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
59. Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C (2003) Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33:301-307
60. Lloyd Jones M, Wilkinson A (2006) Adverse effects and persistence with therapy in patients taking oral alendronate, etidronate or risedronate: a systematic review. NHS R&D HTA ScHARR. http://www.nice.org.uk/nicemedia/ live/11680/36718/36718.pdf Accessed May 12, 2011.
61. (2011) OECD Consumer Price Indices. Available from www.oecd.org/std/ prices-indices. http://stats.oecd.org/Index.aspx? querytype0view&queryname0221. Accessed May 12, 2011.
62. Trombetti A, Herrmann F, Hoffmeyer P, Schurch MA, Bonjour JP, Rizzoli R (2002) Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int 13:731-737
63. Suhm N, Lamy O, Lippuner K (2008) Management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Med Wkly 138:674-683
64. Szucs TD, Hauselmann H (2000) Die Wirtschaftlichkeit von Alendronat in der Behandlung der postmenopausalen Osteoporose. Ökon Qual Manag 5:99-106
65. (2001) Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Available under http://whqlibdoc.who.int/publications/2001/924154550x.pdf. Last accessed October 4th, 2011. Geneva, World Health Organization
66. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7:518-528
67. Borgstrom F, Johnell O, Kanis JA, Jonsson B, Rehnberg C (2006) At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459-1471
68. Swiss Federal Statistical Office (SFSO). Gross Domestic Product per capita. http://www.bfs.admin.ch/bfs/portal/de/index/themen/04/02/01/key/bip- einw.html. Last visited April 18th, 2011.
69. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108-1112
70. Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA (2006) The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 17:1404-1409
71. Sanders KM, Nicholson GC, Watts JJ, Pasco JA, Henry MJ, Kotowicz MA, Seeman E (2006) Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 38:694-700
72. Kanis JA, Mc Closkey E, Jonsson B, Cooper A, Strom O, Borgstrom F (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Archives of Osteoporosis 5:19-48
73. Kanis JA, Reginster JY, Kaufman JM, Ringe JD, Adachi JD, Hiligsmann M, Rizzoli R, Cooper C (2011) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int (in press)
74. Ringe JD, Moller G (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 30:213-221
75. Sheehy O, Kindundu CM, Barbeau M, LeLorier J (2009) Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int 20:1369-1376
76. Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R (2011) Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 22:2565-2573
77. Kanis JA, Jonsson B (2002) Economic evaluation ofinterventions for osteoporosis. Osteoporos Int 13:765-767
78. McCloskey EV, Johansson H, Oden A, VasireddyS, Kayan K, Pande K, Jalava T, Kanis JA (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy - additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811-817
79. Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049-1054
80. Kanis JA, Johansson H, Oden A, McCloskey EV (2010) A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 47:729-735
81. McCloskey E, Lewiecki EM, Kanis JA et al (2011) Denosumab reduces the risk of clinical osteoporotic fractures in post-menopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX®. Osteoporos Int 22(supplement 1):S103
82. Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2011) FRAX® with and without BMD. Calcif Tissue Int (in press)
83. Lippuner K, Popp AW, Schwab P, Gitlin M, Schaufler T, Senn C, Perrelet R (2010) Fracture hospitalizations between years 2000 and 2007 in Switzerland: a trend analysis. Osteoporos Int (in press)
84. Chevalley T, Guilley E, Herrmann FR, Hoffmeyer P, Rapin CH, Rizzoli R (2007) Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend. Bone 40:1284-1289